Skip to main
ORKA

ORKA Stock Forecast & Price Target

ORKA Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oruka Therapeutics is a clinical-stage biopharmaceutical company with a diverse pipeline of monoclonal antibody therapeutics targeting inflammatory and immunological indications, with a primary focus on psoriasis and related conditions. The recent expanded license agreement for its lead program, ORKA-001, provides additional potential for commercial opportunities in the future. ORKA-001 has demonstrated best-in-class efficacy in PsO, and its extended half-life and potential for once-yearly maintenance dosing set it apart from other competitors in the market. With ongoing trials and promising data, Oruka has the potential to become a leader in the IL-23 inhibitor space and attract interest from potential partners or acquirers. Overall, the company has a strong foundation for continued growth and success in the coming years.

Bears say

Oruka Therapeutics is facing financial struggles, as shown by their 1Q26 net loss of $0.48 per share and the need to conduct an upsized equity offering. Additionally, the expected data from the EVERLAST-B trial is not anticipated until 2027, indicating a slow timeline for potential revenue. Furthermore, competition in the psoriasis treatment market is high, with established drugs such as Skyrizi already in the market.

ORKA has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oruka Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oruka Therapeutics Inc (ORKA) Forecast

Analysts have given ORKA a Strong Buy based on their latest research and market trends.

According to 11 analysts, ORKA has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $113.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $113.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oruka Therapeutics Inc (ORKA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.